secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ultragenyx Pharmaceutical Inc. (RARE)
CIK:        0001515673
Form:       8-K
Filed at:   2024-08-01T23:59:59+00:00
Accession:  0000950170-24-089263
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ultragenyx Q2 revenue $147M (+36% YoY), raises 2024 guidance; key FDA agreements advance pipeline
--------------------------------------------------------------------------------

- Q2 total revenue $147M (Crysvita $114M, Dojolvi $19M); net loss narrows to $132M from $160M.
- 2024 revenue guidance raised to $530-550M (prev $500-530M); Crysvita expected towards upper end of $375-400M.
- Cash $874M after June equity offering of $381M net; 2024 operating cash use guided below $400M.
- FDA agrees CSF heparan sulfate as surrogate endpoint for UX111 Sanfilippo accelerated approval; BLA filing late-2024/early-2025.
- Positive Phase 3 data for DTX401 in GSDIa (41.3% reduction in cornstarch, p<0.0001); Phase 2/3 OI setrusumab shows 67% fracture reduction.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1515673/000095017024089263/0000950170-24-089263-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1515673/000095017024089263/rare-20240801.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-089263

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer